Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Marta Bruno Ventre, MD, Marco Foppoli, MD, Giovanni Citterio, MD, Giovanni Donadoni, MD, Maurilio Ponzoni, MD, Silvia Govi, MD, Lydia Scarfò, MD, Marianna Sassone, MD, Federico Caligaris -Cappio, MD, Prof., Andres J.M. Ferreri, MD, PhD

Blood (2013) 122 (21): 4365.

https://doi.org/10.1182/blood.V122.21.4365.4365

Published: 2013

Journal Articles

Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL)

Silvia Govi, MD, Marta Bruno Ventre, MD, Francesco Zaja, Alice Di Rocco, MD, Michele Spina, Daniele Vallisa, MD, Lydia Scarfo', MD, Marianna Chiozzotto, MD, Rosanna Cuccurullo, MD, Angelo Fama, MD, Andrés J.M. Ferreri, MD

Blood (2013) 122 (21): 3055.

https://doi.org/10.1182/blood.V122.21.3055.3055

Published: 2013

Journal Articles

Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ™) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970)

Michele Spina, Stefano Luminari, Andrés J.M. Ferreri, MD, Francesco Zaja, MD, Monica Balzarotti, MD, Flavia Salvi, Moira Micheletti, Gerardo Musuraca, MD, PHD, Elda Viel, MD, Stefano Volpetti, Emanuela Anna Pesce, Marta Bruno Ventre, MD, Massimo Federico, MD

Blood (2012) 120 (21): 3644.

https://doi.org/10.1182/blood.V120.21.3644.3644

Published: 2012

Journal Articles

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

Marta Bruno Ventre, MD, Giovanni Donadoni, MD, Alessandro Re, MD, Michele Spina, MD, Chiara Cattaneo, Luca Fumagalli, MD, Silvia Mappa, MD, Silvia Govi, MD, Giuseppe Rossi, MD, Umberto Tirelli, MD, Andrés JM Ferreri, MD

Blood (2011) 118 (21): 2692.

https://doi.org/10.1182/blood.V118.21.2692.2692

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the IELSG#27 TRIAL)

Silvia Govi, MD, Riccardo Dolcetti, MD, Maurilio Ponzoni, MD, Elisa Pasini, RF, Silvia Mappa, MD, Marta Bruno Ventre, MD, Claudio Doglioni, MD, Francesco Bertoni, MD, Francesco Zaja, MD, Carlos Montalban, MD, PhD, Caterina Stelitano, MD, Maria Elena Cabrera, MD, Franco Cavalli, MD, Emanuele Zucca, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 267.

https://doi.org/10.1182/blood.V118.21.267.267

Published: 2011

Journal Articles

WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.

Blood (2009) 114 (22): 4488.

https://doi.org/10.1182/blood.V114.22.4488.4488

Published: 2009

NARROW

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL)

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL)

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only